A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT.

@article{Pipernoneumann2006AMP,
  title={A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT.},
  author={S Piperno-neumann and Binh Nguyen Bui and Jean-Yves Blay and Henri H. Roch{\'e} and Fabienne Pichon and A Peny and Brigitte Duclos and Marta Jim{\'e}nez and David P{\'e}rol and Axel le Cesne},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={9521}
}
9521 Background: Based on the severe toxicity of high dose methotrexate (MTX) in adult patients, an alternative intensive chemotherapy (CT) was designed, associating doxorubicin, cisplatinum and ifosfamide in API-AI regimen. Promising results in 32 patients in a single institution study (Le Cesne ASCO 2004) led to a national multicenter phase II trial coordinated by the FSG of FNCLCC. METHODS Patients with a localized operable osteosarcoma were eligible. API-AI regimen consisted in 2 cycles… CONTINUE READING